Advisors Management Group Inc. ADV Sells 3,100 Shares of Johnson & Johnson $JNJ

Advisors Management Group Inc. ADV lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 10.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 26,461 shares of the company’s stock after selling 3,100 shares during the quarter. Advisors Management Group Inc. ADV’s holdings in Johnson & Johnson were worth $5,476,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of JNJ. Brighton Jones LLC lifted its stake in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the period. United Bank increased its position in Johnson & Johnson by 110.7% in the first quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after purchasing an additional 4,876 shares during the period. Sivia Capital Partners LLC raised its holdings in Johnson & Johnson by 13.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after purchasing an additional 692 shares during the last quarter. Wealth Group Ltd. lifted its position in Johnson & Johnson by 12.8% during the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock valued at $226,000 after purchasing an additional 168 shares during the period. Finally, Schnieders Capital Management LLC. boosted its stake in shares of Johnson & Johnson by 9.8% in the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock valued at $11,255,000 after purchasing an additional 6,584 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 0.7%

Shares of NYSE JNJ opened at $242.22 on Tuesday. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $251.71. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The stock has a market cap of $583.40 billion, a P/E ratio of 21.92, a P/E/G ratio of 2.37 and a beta of 0.34. The firm has a 50 day moving average price of $237.87 and a 200 day moving average price of $211.39.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion for the quarter. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.1%. Johnson & Johnson’s payout ratio is currently 47.06%.

Analyst Ratings Changes

Several brokerages recently weighed in on JNJ. BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Morgan Stanley set a $253.00 target price on shares of Johnson & Johnson in a report on Wednesday, March 18th. JPMorgan Chase & Co. upped their target price on shares of Johnson & Johnson from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Thursday, March 5th. The Goldman Sachs Group restated a “buy” rating and issued a $250.00 price target on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Finally, Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research note on Friday, January 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $236.91.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares in the company, valued at $6,540,469.77. The trade was a 45.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 30,142 shares of company stock valued at $7,360,528. Insiders own 0.16% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Royalty Pharma agreed to provide $500 million of R&D co‑funding for JNJ‑4804, a novel co‑antibody targeting IL‑23 and TNF; the deal de‑risks development costs, validates the program and accelerates immunology exposure for J&J. Royalty Pharma and J&J partner to develop autoimmune treatment Johnson & Johnson’s JNJ-4804 Deal Adds Weight To Immunology Story
• Positive Sentiment: J&J presented first randomized Phase 2 data for JNJ‑1900 (NBTXR3) in stage‑3 inoperable lung cancer at a major conference — early positive clinical readouts support the oncology pipeline and partner collaborations. NANOBIOTIX Announces Presentation of First Data
• Positive Sentiment: Johnson & Johnson MedTech shared favorable findings for the Impella CP device in left‑ventricular support at ACC, which may support near‑term MedTech revenue momentum and competitive positioning. Johnson & Johnson MedTech shares findings for Impella CP
• Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” rating and a $255 price target, providing analyst backing that supports upside expectations versus current levels. RBC reaffirmation / Benzinga
• Positive Sentiment: Multiple outlets highlighted J&J as a top dividend/defensive stock and noted an upcoming dividend increase window — this bolsters demand from income and defensive investors given J&J’s low beta and long dividend history. This is Why Johnson & Johnson is a Great Dividend Stock Dividend increases coverage
• Neutral Sentiment: Industry research forecasts growth in the non‑muscle invasive bladder cancer market and lists J&J among leading competitors — a positive long‑term market backdrop but not an immediate catalyst. Non‑Muscle Invasive Bladder Cancer Market report

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.